Skip to main content

Day: May 3, 2022

Werner Enterprises Reports First Quarter 2022 Results

First Quarter 2022 Highlights (all metrics compared to first quarter 2021)Total revenues of $764.6 million, up 24% Operating income of $83.5 million, up 34%; non-GAAP adjusted operating income of $86.2 million, up 37% Operating margin of 10.9%, up 80 bps; non-GAAP adjusted operating margin of 11.3%, up 110 bps Diluted EPS of $0.82, up 20%; non-GAAP adjusted diluted EPS of $0.96, up 40%OMAHA, Neb., May 03, 2022 (GLOBE NEWSWIRE) — Werner Enterprises, Inc. (Nasdaq: WERN), a premier transportation and logistics provider, today reported results for the first quarter ended March 31, 2022. “The Werner team once again achieved strong first quarter results in our Truckload Transportation Services and Logistics segments,” said Derek J. Leathers, Chairman, President and Chief Executive Officer. “This was our seventh consecutive quarter...

Continue reading

Benefitfocus Announces First Quarter 2022 Financial Results

Delivered Revenue and Adjusted EBITDA in Excess of Guidance RangesExecuting on Strategic Plan to Return to Sustainable Growth CHARLESTON, S.C., May 03, 2022 (GLOBE NEWSWIRE) — Benefitfocus, Inc. (NASDAQ: BNFT), an industry-leading cloud-based benefits administration technology company that simplifies benefits administration for employers, health plans and brokers, today announces its first quarter 2022 financial results:   Financial Highlights for the First Quarter 2022:First quarter 2022 revenue of $61.2 million was above the high end of the guidance range of $59 to $61 million. Adjusted EBITDA of $11.2 million during the first quarter was above the high end of the guidance range of $7 to $9 million. GAAP net loss available to common stockholders was ($3.9) million, compared to ($3.7) million in the first quarter of 2021.   GAAP...

Continue reading

New York Mortgage Trust Reports First Quarter 2022 Results

NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) — New York Mortgage Trust, Inc. (Nasdaq: NYMT) (“NYMT,” the “Company,” “we,” “our” or “us”) today reported results for the three months ended March 31, 2022. Summary of First Quarter 2022: (dollar amounts in thousands, except per share data)Net loss attributable to Company’s common stockholders $ (84,343 )Net loss attributable to Company’s common stockholders per share (basic) $ (0.22 )Undepreciated loss (1) $ (64,205 )Undepreciated loss per common share (1) $ (0.17 )Comprehensive loss attributable to Company’s common stockholders $ (86,531 )Comprehensive loss attributable to Company’s common stockholders per share (basic) $ (0.23 )Yield on average interest earning assets   6.80 %Net interest income $ 29,879  Portfolio net interest income...

Continue reading

Pulmonx Reports First Quarter 2022 Financial Results

REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter ended March 31, 2022. Recent HighlightsRecorded worldwide revenue of $10.8 million in the first quarter of 2022, a 17% increase over the same period last year and an increase of 20% on a constant currency basis Realized gross margin of 75% in the first quarter of 2022 as compared to 72% in the same period last year Added 16 new U.S. treatment centers for Zephyr Valves in the first quarter 2022, increasing total U.S. treatment centers to 230“We are encouraged by our first quarter performance as we benefited from a strong recovery in procedure volumes and account activity in the...

Continue reading

Landsea Homes Reports First Quarter 2022 Results

First Quarter 2022 HighlightsExpanded home sales revenue 92.5% to $298 million First quarter net income of $13.1 million, $0.28 per diluted share Total homes delivered increased 83.4% to 552 homes Increased backlog by 83.4% to 1,605 homes for a total of $930.4 million Adjusted home sales gross margin increased to 29.0%, from 17.9% Authorized the repurchase of up to an additional $10 million shares of common stock, increasing the aggregate to up to $20 millionNEWPORT BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) — Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”), a publicly traded homebuilder, reported financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights vs. First Quarter 2021:Total revenue grew 97.1% to $316.2 million compared to $160.4 million. Total homes...

Continue reading

Talkspace Reports 2022 First Quarter Results

Revenue grew 11% year over year to $30 millionStrong growth in B2B, with sessions growing 68% and eligible lives up 54% versus the prior yearB2C customer acquisition metrics demonstrated improvement quarter-over-quarter NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) — Talkspace, Inc. (Nasdaq: TALK), a leading virtual behavioral healthcare company, today reported 2022 first quarter results as summarized below. All financial results refer to 2022 first quarter and the prior-year period unless otherwise stated.    Three Months  Period ended March 31, 2022   Results     Variance from Prior Year  (In thousands unless otherwise noted, unaudited)            Number of B2B eligible lives (in millions)     76.5       54 %Number of active members 1     64.5       10 %Number of completed B2B sessions     90.6       68 %             Total...

Continue reading

Regency Centers Reports First Quarter 2022 Results

JACKSONVILLE, Fla., May 03, 2022 (GLOBE NEWSWIRE) — Regency Centers Corporation (“Regency” or the “Company”) (Nasdaq: REG) today reported financial and operating results for the period ended March 31, 2022 and provided updated guidance for 2022 Nareit FFO. For the three months ended March 31, 2022 and 2021, Net Income was $1.14 per diluted share and $0.47 per diluted share, respectively. First Quarter 2022 HighlightsReported Nareit FFO of $1.03 per diluted share for the first quarter Raised 2022 Nareit FFO guidance to a range of $3.84 to $3.90 per diluted share Reported that Same Property Net Operating Income (“NOI”) during the first quarter increased 7.8% excluding lease termination fees, and increased 14.9% excluding lease termination fees and prior year collections, over the same period a year ago Increased percent commenced...

Continue reading

Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals

Deal includes up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earn out payments on net sales to Brickell Sale reflects Brickell’s strategic shift into the immunology and inflammation fields; proceeds will be used to advance Company’s pipeline of recently acquired novel therapies BOULDER, Colo., May 03, 2022 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or “Company”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, announced today that it has signed and closed a definitive asset purchase agreement with Botanix SB...

Continue reading

Rattler Midstream LP, a Subsidiary of Diamondback Energy, Inc., Reports First Quarter 2022 Financial and Operating Results

MIDLAND, Texas, May 03, 2022 (GLOBE NEWSWIRE) — Rattler Midstream LP (NASDAQ: RTLR) (“Rattler” or the “Company”), a subsidiary of Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback”), today announced financial and operating results for the first quarter ended March 31, 2022. FIRST QUARTER 2022 HIGHLIGHTSQ1 2022 consolidated net income (including non-controlling interest) of $37.1 million Q1 2022 consolidated Adjusted EBITDA (as defined and reconciled below) of $87.0 million Q1 2022 cash flow provided by operating activities of $59.9 million Q1 2022 cash operated capital expenditures of $17.9 million Q1 2022 consolidated Free Cash Flow (as defined and reconciled below) of $44.9 million Board of Directors of Rattler’s general partner approved a cash distribution for the first quarter of 2022 of $0.30 per common unit ($1.20...

Continue reading

Guardion Health Sciences to Present at the Planet MicroCap Showcase 2022

HOUSTON, May 03, 2022 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (Nasdaq: GHSI), a clinical nutrition company that develops clinically supported nutrition, medical foods, and supplements, announces today that Chief Executive Officer Bret Scholtes will present a corporate overview at the Planet MicroCap Showcase 2022. The conference is being held on May 3 – 5, 2022 at The Bally’s Hotel & Casino in Las Vegas, NV.Presentation Date: May 4, 2022   Time: 5:00pm Pacific Time   Webcast Link: https://www.webcaster4.com/Webcast/Page/2862/45120Mr. Scholtes will be available for one-on-one meetings. To request a meeting and to register for the conference, click here: https://planetmicrocapshowcase.com/signup About Guardion Health Sciences, Inc. Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical nutrition...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.